Phoenix Group, the German-based pharmaceutical wholesale and retail giant that owns the Rowlands and Numark pharmacy brands in the UK, has posted robust annual results despite a “volatile market environment”.
Over the year to 31 January 2025, the group’s total revenue rose by 5.7% to €49.7bn, with all regions achieving growth as it “countered ongoing political and economic challenges with great operational strength” in its 30th anniversary year.
Adjusted for one-off effects, EBITDA rose 17.5% to €1.1bn, with pre-tax profit increasing from €344.3m to €465.5m.
“Over the past 30 years, the Phoenix group has transformed itself from a German pharmaceutical wholesaler into Europe’s leading healthcare provider,” said Chief Executive Sven Seidel.
“We are aware of the special responsibility that the Phoenix group has towards healthcare systems in Europe. That is why we are focusing on strengthening our resilience in order to rise above current and future challenges and continue to fulfil our mission: ‘We deliver health.’”
For the year ahead, the group stated that it anticipates further expansion of its market position in Europe through organic growth and acquisitions, resulting in a slight increase in revenue in nearly all markets in which it is present. Meanwhile, it expects a “moderate increase” in pre-tax profit.
NAM Implications:
- Phoenix is patently firing on all cylinders.
- Key standout has to be:
- ‘anticipates further expansion of its market position in Europe through organic growth and acquisitions’.
- Meaning takeovers of weaker rivals.
- i.e. key for suppliers to try to anticipate target wholesalers and retailers…
- …and ensure their prices and terms are harmonised…
- …before Phoenix does it on their behalf.
